The effects of blood pressure and lipid control on kidney allograft outcome

被引：11

作者：

El-Amm J.-M. ^{[1
]}

Haririan A. ^{[1
]}

Crook E.D. ^{[1
,2
,3
]}

机构：

[1] Wayne State University, School of Medicine, Detroit, MI

[2] John D. Dingell Veteran Affairs Medical Center, Detroit, MI

[3] Mastin 400A, Mobile, AL 36617-2293

来源：

American Journal of Cardiovascular Drugs | 2006年 / 6卷 / 1期

关键词：

Chronic Kidney Disease; Acute Rejection; Graft Survival; Mycophenolate Mofetil; Fluvastatin;

D O I：

10.2165/00129784-200606010-00001

中图分类号：

学科分类号：

摘要：

Despite the improvement in short- and long-term kidney allograft survival in recent years, a significant number of grafts are lost because of chronic allograft nephropathy (CAN) or death secondary to cardiovascular disease (CVD). There is growing evidence that both hypertension and hyperlipidemia play important roles in the progression of CAN and CVD in kidney transplant recipients. Large, randomized, controlled studies to determine the optimal target levels for BP and serum lipids, as well as the choice of drug therapy, are lacking. However, based on the available data, we suggest that currently recommended target levels in non-transplant patients should also be used after transplantation. We believe that achieving these target levels for BP and serum lipids are of primary importance, and that the non-lipid-lowering effects of HMG-CoA reductase inhibitors might exert additional benefits in prolonging graft survival. © 2006 Adis Data Information BV. All rights reserved.

引用

页码：1 / 7

页数：6

共 57 条

[1]

Hariharan S., Johnson C.P., Bresnahan B.A., Et al., Improved graft survival after renal transplantation in the United States, 1988 to 1996, N Engl J Med, 342, 9, pp. 605-612, (2000)

[2]

Kasiske B.L., Gaston R.S., Gourishankar S., Et al., Long-term deterioration of kidney allograft function, Am J Transplant, 5, 6, pp. 1405-1414, (2005)

[3]

K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease, Am J Kidney Dis, 41, 4 SUPPL. 3, (2004)

[4]

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease, Am J Kidney Dis, 43, 1 SUPPL., (2004)

[5]

Karthikeyan V., Karpinski J., Nair R.C., Et al., The burden of chronic kidney disease in renal transplant recipients, Am J Transplant, 4, 2, pp. 262-269, (2004)

[6]

Midtvedt K., Neumayer H.H., Management strategies for post transplant hypertension, Transplantation, 70, 11 SUPPL., (2000)

[7]

Ligtenberg G., Hene R.J., Blankestijn P.J., Et al., Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus, J Am Soc Nephrol, 12, 2, pp. 368-373, (2001)

[8]

Budde K., Waiser J., Fritsche L., Et al., Hypertension in patients after renal transplantation, Transplant Proc, 29, 1-2, pp. 209-211, (1997)

[9]

Perez Fontan M., Rodriguez-Carmona A., Garcia Falcon T., Et al., Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation, Am J Kidney Dis, 33, 1, pp. 21-28, (1999)

[10]

Textor S.C., Canzanello V.J., Taler S.J., Et al., Cyclosporine-induced hypertension after transplantation, Mayo Clin Proc, 69, 12, pp. 1182-1193, (1994)

← 1 2 3 4 5 6 →